Blueprint Medicines Corporation (BPMC) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Blueprint Medicines Corporation (BPMC) Bundle
Designed for accuracy, our Blueprint Medicines Corporation (BPMC) DCF Calculator enables you to assess the valuation of Blueprint Medicines Corporation with real-world financial data, offering complete flexibility to modify all essential parameters for improved projections.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 66.5 | 793.7 | 180.1 | 204.0 | 249.4 | 285.7 | 327.2 | 374.9 | 429.4 | 491.9 |
| Revenue Growth, % | 0 | 1093.37 | -77.31 | 13.3 | 22.22 | 14.55 | 14.55 | 14.55 | 14.55 | 14.55 |
| EBITDA | -356.1 | 308.7 | -628.3 | -515.4 | -470.4 | -206.3 | -236.3 | -270.7 | -310.1 | -355.3 |
| EBITDA, % | -535.34 | 38.89 | -348.9 | -252.61 | -188.61 | -72.22 | -72.22 | -72.22 | -72.22 | -72.22 |
| Depreciation | 10.3 | 12.4 | 12.8 | 20.1 | 11.7 | 22.1 | 25.3 | 28.9 | 33.1 | 38.0 |
| Depreciation, % | 15.41 | 1.56 | 7.1 | 9.85 | 4.68 | 7.72 | 7.72 | 7.72 | 7.72 | 7.72 |
| EBIT | -366.3 | 296.4 | -641.1 | -535.5 | -482.0 | -207.2 | -237.4 | -271.9 | -311.5 | -356.8 |
| EBIT, % | -550.75 | 37.34 | -356 | -262.46 | -193.29 | -72.53 | -72.53 | -72.53 | -72.53 | -72.53 |
| Total Cash | 548.0 | 1,549.7 | 1,034.6 | 1,078.5 | 710.6 | 285.7 | 327.2 | 374.9 | 429.4 | 491.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 23.4 | 25.3 | 37.0 | 36.9 | 43.2 | 53.9 | 61.8 | 70.8 | 81.1 | 92.8 |
| Account Receivables, % | 35.2 | 3.19 | 20.56 | 18.1 | 17.31 | 18.87 | 18.87 | 18.87 | 18.87 | 18.87 |
| Inventories | -434.0 | 8.6 | 21.8 | 29.7 | 21.2 | -36.4 | -41.7 | -47.8 | -54.7 | -62.7 |
| Inventories, % | -652.55 | 1.08 | 12.12 | 14.55 | 8.51 | -12.75 | -12.75 | -12.75 | -12.75 | -12.75 |
| Accounts Payable | 4.8 | 4.4 | 8.3 | 2.7 | 4.7 | 8.9 | 10.2 | 11.7 | 13.4 | 15.4 |
| Accounts Payable, % | 7.21 | 0.55056 | 4.63 | 1.34 | 1.89 | 3.12 | 3.12 | 3.12 | 3.12 | 3.12 |
| Capital Expenditure | -14.0 | -3.2 | -261.2 | -8.9 | -16.1 | -75.6 | -86.6 | -99.2 | -113.6 | -130.1 |
| Capital Expenditure, % | -21.07 | -0.39799 | -145.07 | -4.37 | -6.44 | -26.46 | -26.46 | -26.46 | -26.46 | -26.46 |
| Tax Rate, % | -0.1913 | -0.1913 | -0.1913 | -0.1913 | -0.1913 | -0.1913 | -0.1913 | -0.1913 | -0.1913 | -0.1913 |
| EBITAT | -346.3 | 295.4 | -644.1 | -540.6 | -482.9 | -204.8 | -234.6 | -268.8 | -307.9 | -352.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 65.3 | -140.4 | -913.5 | -542.8 | -483.1 | -207.2 | -297.2 | -340.4 | -390.0 | -446.7 |
| WACC, % | 6.86 | 6.88 | 6.89 | 6.89 | 6.89 | 6.88 | 6.88 | 6.88 | 6.88 | 6.88 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1,352.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -456 | |||||||||
| Terminal Value | -9,337 | |||||||||
| Present Terminal Value | -6,695 | |||||||||
| Enterprise Value | -8,047 | |||||||||
| Net Debt | 703 | |||||||||
| Equity Value | -8,750 | |||||||||
| Diluted Shares Outstanding, MM | 61 | |||||||||
| Equity Value Per Share | -144.48 |
What You Will Get
- Real BPMC Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Automated Calculations: Intrinsic value and NPV are computed in real-time.
- Scenario Analysis: Evaluate various scenarios to assess Blueprint Medicines Corporation’s future performance.
- User-Friendly Design: Designed for professionals while remaining approachable for newcomers.
Key Features
- 🔍 Real-Life BPMC Financials: Pre-filled historical and projected data for Blueprint Medicines Corporation (BPMC).
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Blueprint Medicines' intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Blueprint Medicines' valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Blueprint Medicines Corporation (BPMC) data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Blueprint Medicines Corporation (BPMC)’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose Blueprint Medicines Corporation (BPMC)?
- Innovative Treatments: Pioneering therapies for patients with genomically defined cancers.
- Expertise in Precision Medicine: Focused on targeted therapies that address unmet medical needs.
- Strong Pipeline: Robust development of drug candidates with significant potential.
- Commitment to Patients: Dedicated to improving the lives of those affected by rare diseases.
- Proven Track Record: Backed by a team of industry leaders with extensive experience.
Who Should Use This Product?
- Healthcare Professionals: Understand the latest advancements in precision medicine and their applications.
- Researchers: Utilize comprehensive data and models for studies related to targeted therapies.
- Investors: Evaluate your strategies and assess the potential of Blueprint Medicines Corporation (BPMC) in your portfolio.
- Pharmaceutical Analysts: Enhance your analysis with a customizable model for drug development valuations.
- Biotech Entrepreneurs: Learn from the market strategies of established companies like Blueprint Medicines Corporation (BPMC).
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Blueprint Medicines Corporation (BPMC) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), featuring parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models displaying intrinsic value with comprehensive calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to facilitate thorough analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios specific to Blueprint Medicines Corporation (BPMC).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions for easy analysis of results.